Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC
Last Updated: Friday, March 25, 2022
Single-agent osimertinib is the standard of care for the first-line treatment of advanced EGFR+ NSCLC. This review profiles many of the third-generation EGFR TKIs in late-stage clinical development (e.g., almonertinib, lazertinib, alflutinib1, rezivertinib, ASK120069, SH-1028, D-0316, and abivertinib) based on their interim results from phase 1 and phase 2 trials.
Advertisement
News & Literature Highlights
